Release Date: 13-Jul-2024
Immune checkpoint-directed therapies have revolutionized cancer treatment by unleashing the body's immune system to combat tumors effectively. While agents targeting prominent checkpoints like PD-1/PD-L1 and CTLA-4 have shown remarkable success, there is a growing recognition of other immune checkpoints that hold promise as novel therapeutic targets. Among these emerging targets, Human Leukocyte Antigen-G (HLA-G) has garnered considerable attention in recent years for its role in immune evasion and tumor progression. The exploration of HLA-G as a novel immune checkpoint opens new avenues for cancer therapy, offering innovative strategies to overcome immune suppression within the tumor microenvironment.
HLA-G is a non-classical major histocompatibility complex (MHC) molecule that plays a crucial role in immune tolerance during pregnancy. But in cancer, HLA-G is aberrantly produced by tumor cells, which suppresses T cells, NK cells, and antigen-presenting cells, among other immune cell types, hence impeding the anti-tumor immune response. HLA-G targeting is a unique strategy to cancer immunotherapy that may help boost the body's anti-tumor immune response and get beyond resistance mechanisms.
As the most developed candidate in clinical development and the first-in-class HLA-G-targeting antibody, Tizona Therapeutics' TTX-080 is a trailblazing drug in the field of HLA-G-targeted therapy. The anti-HLA-G antibody TTX-080 is administered and binds to HLA-G. This prevents HLA-G from binding to its inhibitory receptors on immune cells, including dendritic cells (DCs), T and B lymphocytes, and NK cells. This may inhibit HLA-G-mediated immune suppression, triggering both innate and adaptive immunological responses. TTX-080 is now being tested in a phase 1b clinical trial as a single agent and in combination with pembrolizumab and cetuximab for the treatment of advanced solid tumors in patients with refractory or resistant solid malignancies.
Another intriguing approach to targeting HLA-G is the development of HLA-G-directed chimeric antigen receptor (CAR)-T cell therapy. Invectys' IVS-3001 is a first-in-class HLA-G-directed CAR-T cell treatment that targets and eliminates HLA-G-expressing tumor cells. This novel method combines CAR-T cells' potent anti-tumor activity with the capacity to target the immunosuppressive HLA-G pathway. Additionally, in July 2023, Invectys declared that IVS-3001 had received Fast Track designation from the FDA due to its potential to address the treatment gap among individuals diagnosed with HLA-G positive locally advanced or metastatic clear cell renal cell carcinoma (RCC), who have either not responded well to conventional RCC treatments or cannot tolerate them.
IVS-3001 IVS-3001 is currently in a phase 1/2 study that is investigating its safety, tolerability, pharmacokinetics and clinical activity in subjects with previously treated, locally advanced, or metastatic solid tumors which are HLA-G+.
In summary, the advancement of TTX-080 and IVS-3001 in clinical development represents a significant step forward in the HLA-G-targeted therapeutics market. As they progress through trials and demonstrate efficacy across various cancers, they could revolutionize treatment, particularly for patients with HLA-G-overexpressing tumors. Moreover, their success may spur the development of additional HLA-G-targeted therapies. Overall, these advancements underscore the growing importance of HLA-G as a therapeutic target in cancer and the potential for HLA-G-targeted therapies to reshape cancer care.
For Clinical Trials Information Contact